ESMO Archives -

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of

At ESMO, three studies show promise of antibody-drug conjugates in breast cancer

https://pharmaphorum.com/oncology/esmo-three-studies-show-promise-antibody-drug-conjugates-breast-cancer/

ESMO21: Enhertu brings it’s A game to second-line breast cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, ESMO, HER2-positive breast cancer, Kadcyla, Roche 0 Comment

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC)

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

News/ News/ Oncology

ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs

Phil Taylor breast cancer, ESMO, Giredestrant, Oncology, Roche 0 Comment

Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective

ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs

https://pharmaphorum.com/news/esmo21-roches-giredestrant-takes-stage-in-battle-of-the-oral-serds/

News/ News/ Oncology

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

Phil Taylor Amgen, Boehringer Ingelheim, colorectal cancer, ESMO, KRAS, Lumakras, Oncology, Vectibix 0 Comment

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

https://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Immunomedics wows ESMO with breast cancer data reveal

Richard Staines breast cancer, ESMO, Gilead, Immunomedics, Roche, triple negative breast cancer 0 Comment

Immunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s

Immunomedics wows ESMO with breast cancer data reveal

https://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/

Oncology/ Views & Analysis/ Views and analysis

ESMO 2019 roundup

Richard Staines AbbVie, Amgen, AstraZeneca, cancer, Clovis, ESMO, GSK, Merck & Co 0 Comment

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

News/ News/ Oncology

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

Phil Taylor AbbVie, AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, Zejula 0 Comment

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

News/ News/ News/ Oncology/ R&D

ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challenge

Phil Taylor Amgen, colorectal cancer, ESMO, Oncology 0 Comment

Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported

ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challenge

https://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/

News/ News/ Oncology

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

Phil Taylor AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, PARP inhibitor, Zejula 0 Comment

GlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

Trending

ESMO

Login